Who are Duvie's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Placebo then Pioglitazone, duvie, Pioglitazone, Rosiglitazone, Pioglitazone - TZD, Pioglitazone Tablets, MESA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lobeglitazone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Duvie — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Duvie (LOBEGLITAZONE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Metabolic.

marketed Peroxisome proliferator-activated receptor gamma Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Duvie (LOBEGLITAZONE) — Chong Kun Dang.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Duvie TARGET	LOBEGLITAZONE	Chong Kun Dang	marketed		Peroxisome proliferator-activated receptor gamma
Placebo then Pioglitazone	Placebo then Pioglitazone	Medical University of South Carolina	marketed	Thiazolidinedione	PPAR-γ (Peroxisome proliferator-activated receptor gamma)
duvie	duvie	Pusan National University Hospital	marketed		Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor gamma
Pioglitazone, Rosiglitazone	Pioglitazone, Rosiglitazone	Korea University Anam Hospital	marketed	Thiazolidinedione (PPAR-γ agonist)	PPAR-γ (Peroxisome proliferator-activated receptor gamma)
Pioglitazone - TZD	Pioglitazone - TZD	Royal Devon and Exeter NHS Foundation Trust	marketed	Thiazolidinedione (TZD)	PPAR-γ (Peroxisome proliferator-activated receptor gamma)
Pioglitazone Tablets	Pioglitazone Tablets	Peking Union Medical College Hospital	marketed	Thiazolidinedione (PPAR-γ agonist)	PPAR-γ (Peroxisome proliferator-activated receptor gamma)
MESA	MESA	Meda Pharms	marketed		Arachidonate 5-lipoxygenase, Peroxisome proliferator-activated receptor gamma, Prostaglandin G/H synthase 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Duvie — Competitive Intelligence Brief. https://druglandscape.com/ci/lobeglitazone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing